| Document |
Document Title |
|
WO/2019/033247A1 |
Provided is a method for establishing a cell line with stable and high expression of the SISP1 gene, the method comprising: (1) inserting the coding sequence of the SISP1 gene into multiple cloning sites of an eukaryotic expression vecto...
|
|
WO/2019/035618A1 |
The present invention relates to a method for culturing a 3-dimensional lung cancer organoid and a method for preparing a patient-derived xenograft animal model using the same. More specifically, the present invention relates to a method...
|
|
WO/2019/036375A1 |
This disclosure relates to cardiogenic mesoderm formation regulators and methods of use thereof, e.g., generating a multipotent cardiovascular progenitor cell by overexpressing Id1, Id2, Id3, Id4, Evx1, and/or Grrp1 in a stem cell.
|
|
WO/2019/035436A1 |
Provided is a culture substrate capable of culturing pluripotent stem cells in a feeder-free environment and capable of detaching pluripotent stem cells from the substrate without using a protease by changing the temperature of the subst...
|
|
WO/2019/034550A1 |
The present invention refers to an in vitro method for producing a flap of genetically modified 5 cells on fibrin substrate and to the flap so obtained.
|
|
WO/2019/036343A1 |
The subject invention provides methods of treating neurological disease or disorder, such as brain injuries, such as stroke, traumatic brain injury (TBI), or other ischemic events that cause brain injury by inhibiting or down-regulating ...
|
|
WO/2019/034027A1 |
Provided are a method for expressing target genes and a dedicated specific DNA molecule thereof. A nucleotide sequence of the specific DNA molecule is shown in 7 to 589 sites of a sequence 1 starting from 5' tail ends in a sequence table...
|
|
WO/2019/035901A1 |
The present disclosure relates, in general, to inhibiting signaling activity of STING (STimulator of INterferon Genes) in a subject having an ongoing immune response and use of constitutively active STING mutants to stimulate an immune r...
|
|
WO/2019/033482A1 |
Provided is a method for directional differentiation of human pluripotent stem cells. The method comprises cultivating human pluripotent stem cells in a clearly-composed cell culture environment without exogenous hematopoietic cytokines,...
|
|
WO/2019/035476A1 |
The purpose of the present invention is to provide a method for constructing a device for causing a plurality of receptors to be expressed in respectively different eukaryotic cells upon nucleic acids within through-holes, housing a plur...
|
|
WO/2019/036599A1 |
CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene and absence or deficiency of dystrophin protein in...
|
|
WO/2019/036232A1 |
A well for electrically stimulating at least one cell. The well includes a bottom portion and comprises an adaptive electrode arrangement for introducing an electric field into the well. The adaptive electrode arrangement includes a pair...
|
|
WO/2019/034615A1 |
The present invention relates to a method for the production of cells having a cardiomyocyte phenotype, comprising: (a) overexpression of EOMES in embryonic stem cells or induced pluripotent stem cells for about 1 to 6 days, preferably 2...
|
|
WO/2019/036720A1 |
Cystic fibrosis therapy and compositions for cystic fibrosis therapy are disclosed. Methods of modulating autophagy activity and compositions for modulating autophagy activity are disclosed. In specific aspects, antagomirs that comprise ...
|
|
WO/2019/035070A1 |
Provided are methods of in vitro maturation of human spermatogonium, comprising culturing the spermatogonium in a three-dimensional methylcellose culture system (MCS) under conditions capable of differentiating said human spermatogonium ...
|
|
WO/2019/036086A1 |
The present disclosure involves the use of reprogramming factors including AKT1, GATA4, TBX5, MEF2C, HAND2 and either ZNF281 or ASCLl to reprogram adult non- cardiomyocytes, such as cardiac fibroblasts into cardiomyocytes, both in vitro ...
|
|
WO/2019/033824A1 |
The present invention mainly belongs to the technical field of tumor immunology, and particularly relates to a novel human bladder cancer marker AG-CD71 and a monoclonal antibody ABC71 for preventing AG-CD71. The human bladder cancer mar...
|
|
WO/2019/035462A1 |
The present invention provides a method for position-specific determination of the undifferentiated state of pluripotent stem cells cultured in a cell culture container wherein a cell culture container provided with one flow path that is...
|
|
WO/2019/035880A1 |
Provided herein are isolated exosomes from mesenchymal stem cells (MSC). Such isolated exosomes are substantially free of contaminants and are therapeutically active in treating various diseases (e.g., lung diseases such as BPD). The iso...
|
|
WO/2019/034966A1 |
The present invention refers to a reliable and reproducible industrialisation method for the elimination of air bubbles in the production of an engineered vascular tissue for in vitro testing of medical products for human use and veterin...
|
|
WO/2019/036594A1 |
A method is disclosed for coating and patterning hydrogels in order to modify surface properties. The method exploits the water content of the hydrogel and the hydrophobicity of the reaction solvent to create a thin oxide adhesion layer ...
|
|
WO/2019/029713A1 |
Provided is a method of using a CHO host cell with an edited genome in producing a recombinant antibody having a unique glycan profile. The method uses TALEN technology to edit fut8 gene of a CHO cell that has been adapted to serum-free ...
|
|
WO/2019/029084A1 |
Provided is an artificial endometrium and a preparation method and application thereof. The artificial endometrium comprises a biocompatible stent, endometrial stromal cells/epithelial cells, and a mixed culture. With a 3D bioprinting te...
|
|
WO/2019/024933A1 |
Provided is a chimeric antigen receptor NK cell expressing specific recognition for GPC3 and preparation method therefor, as well as a use of the cell in prevention and/or treatment of cancers, especially a GPC3-expression cancer. Also p...
|
|
WO/2019/023793A1 |
Provided herein are methods of producing, compositions comprising and uses of oligodendrogenic neural progenitor cells (o-NPCs), made using a combination of PDGFR agonist and thyroxin or a thyroxin analogue. The method includes; obtainin...
|
|
WO/2019/026903A1 |
The present invention provides a method for evaluating the tumorigenicity of test cells, the method including transplanting the cells into the anterior chamber of an experimental animal and observing the presence/absence of tumor formati...
|
|
WO/2019/028051A1 |
Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the ch...
|
|
WO/2019/028094A1 |
The present invention provides an isolated population of cortical bone stem cell (CBSC)-derived exosomes, and compositions comprising the exosomes and/or RNA thereof, for promoting cardiac repair when delivered to a diseased heart.
|
|
WO/2019/026948A1 |
[Problem] To provide a vector including a transcription factor and a promotor expressed specifically in the fiber structure of a plant, particularly cotton. [Solution] A vector including at least one promotor expressed specifically in co...
|
|
WO/2019/027298A2 |
The present invention relates to a pharmaceutical composition comprising mesenchymal stem cells expressing TRAIL and CD as an effective ingredient for prevention or treatment of cancer. A pharmaceutical composition comprising TRAIL- and ...
|
|
WO/2019/027299A2 |
The present invention relates to a pharmaceutical composition for preventing or treating vascular disorders including a mesenchymal stem cell expressing a hepatocyte growth factor (HGF) protein as an active ingredient. This pharmaceutica...
|
|
WO/2019/024579A1 |
The present invention provides a gene marker for detecting a lung cancer, a kit, and a lung cancer detection method. According to the present invention, the content of 5-hydroxymethylcytosine in one or more genes of RUNX1 transposition p...
|
|
WO/2019/024578A1 |
The present invention provides a gene marker for detecting benign and malignant liver tumors, a kit, and a detection method. According to the present invention, the content of 5-hydroxymethylcytosine in one or more marker genes of FAT at...
|
|
WO/2019/025800A1 |
The present invention provides a cell which expresses a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), the cell comprising a nucleotide sequence of interest (NOI) which is selectively expressed by the cell depend...
|
|
WO/2019/023806A1 |
A plant or plant cell with reduced endogenous AGO1 and AGO4 expression compared to a wild-type plant or plant cell is provided. In one embodiment, the plant or plant cell further comprises a nucleic acid sequence encoding a recombinant p...
|
|
WO/2019/025984A1 |
Cellular models for diseases of eyes, methods and compositions for treating diseases in eyes are provided.
|
|
WO/2019/028223A1 |
Described herein are methods and compositions related to treating cancer using cardiosphere derived cells (CDCs) and/or extracellular vesicles (EVs). In some embodiments, the EVs are heart-derived EVs (e.g., cardiosphere-derived exosomes...
|
|
WO/2019/025826A1 |
The invention relates to a method of providing CD31+ cells suitable for forming 3D vascular construct, said cells expressing an increased amount of angiogenesis related and cell-matrix adhesion related proteins and having an arterial phe...
|
|
WO/2019/027834A1 |
The present application is directed to compositions and methods for establishing organoid cultures from cryogenically preserved tissue (e.g., human biopsy tissue), and related methods of use with such established organoid cultures.
|
|
WO/2019/026910A1 |
The present invention enables cryopreservation whereby very few cells are killed and good qualities are retained. The composition for cryopreservation according to one embodiment of the present invention, which is to be used for cryopres...
|
|
WO/2019/027214A2 |
The present invention relates to an allogeneic mesenchymal stem cell and a use thereof, wherein, due to the inclusion of a step for treating a mesenchymal stem cell with an interferon gamma and a proteasome inhibitor, a mesenchymal stem ...
|
|
WO/2019/025070A1 |
A method for the preparation of a three-dimensional hydrogel scaffold for cell culturing, which comprises the steps of: a) preparing at least one first uniform solid mixture comprising at least one gas-forming agent, at least one water-s...
|
|
WO/2019/028028A1 |
The disclosure provides methods and compositions for labelling, detecting, quantifying, and monitoring activated allergen-specific T cells. The disclosed methods and compositions can be applied to further detect allergic states or monito...
|
|
WO/2019/028295A1 |
The present disclosure relates to particular subsets of CD4+ and CD8+ T-cells, methods of isolating and generating these cells, compositions comprising these cells, and methods of treatment of a tumor or cancer by administering these cel...
|
|
WO/2019/028131A1 |
Provided herein according to some embodiments is an in vitro construct useful as a model for a hematopoietic microenvironment, which may include: a microfluidic device having multiple chambers; and two or more populations of cells (e.g.,...
|
|
WO/2019/028427A1 |
The present invention in various aspects and embodiments involves pharmaceutical compositions prepared by contacting a candidate a- or β-integrin-binding molecule, or panel thereof, with an integrin heterodimer, and quantifying heterodi...
|
|
WO/2019/028337A1 |
Described herein are methods for treating or preventing leukemias with NK-92 cells. In particular, provided are methods of treating or preventing leukemias by administering to a patient one or more doses of NK-92 cells for killing remnan...
|
|
WO/2019/027850A1 |
The present disclosure provides compositions and methods for stimulating, enriching, expanding, and/or activating engineered cells that express a recombinant receptor, e.g., a chimeric antigen receptor. In some embodiments, the provided ...
|
|
WO/2019/023961A1 |
Disclosed is a method for capturing target cells or molecules in solution, comprising steps of: (I) getting medium containing said target cells or molecules into an apparatus comprising a capturing device for capturing said target cells ...
|
|
WO/2019/023396A1 |
Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their ...
|
